Posts tagged AI
Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated. We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

Read More
BenevolentAI Awarded Technology Pioneer Status by World Economic Forum

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Read More
Love drug discovery? You just need the right chemistry!

There is an increasing number of varieties of drug agents in clinical use ranging from antibodies and proteins to nucleic acids and, increasingly, cellular and genetic therapies but the majority of drugs on the market and in development today are still small, synthetic molecules made in a chemistry laboratory.

Read More
Counting down to the BenevolentAI Award

It’s now only a number of days until we announce the winner of the first BenevolentAI award on March 28th. Since applications closed in late January, the process has been one my fellow judges, Aisling Burnand, CEO of Association of Medical Research Charities (AMRC), and Neil Lawrence, Director of Machine Learning of Amazon Research Cambridge and I have found enjoyable, insightful and richly rewarding.

Read More